About Novelos Therapeutics
Novelos Therapeutics is a company based in Madison (United States) founded in 1998 by Jamey Weichert. Novelos Therapeutics has raised $53.85 million across 5 funding rounds. Novelos Therapeutics has completed 1 acquisition, including Cellectar Biosciences. Novelos Therapeutics operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Lantheus, among others.
- Headquarter Madison, United States
- Founders Jamey Weichert
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$53.85 M (USD)
in 5 rounds
-
Latest Funding Round
$4 M (USD), Unspecified
Feb 07, 2014
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Novelos Therapeutics
Novelos Therapeutics has successfully raised a total of $53.85M across 5 strategic funding rounds. The most recent funding activity was a Unspecified round of $4 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Novelos Therapeutics
Novelos Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cellectar Biosciences.
Investment portfolio details for Novelos Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Phospholipid drug conjugates for cancer treatment are developed.
|
Locked | Locked | 2002 | Locked |
Complete acquisition details for Novelos Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Novelos Therapeutics
Detailed financials for Novelos Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novelos Therapeutics Comparisons
Peer comparison for Novelos Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novelos Therapeutics
Novelos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Lantheus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| Locked | Locked | Locked |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
|
| Locked | Locked | Locked |
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
|
|
| Locked | Locked | Locked |
Developer of diagnostic imaging agents and targeted therapeutics
|
|
| Locked | Locked | Locked |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
Detailed competitors of Novelos Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novelos Therapeutics
Complete news archive for Novelos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novelos Therapeutics
Novelos Therapeutics was founded in 1998 and raised its 1st funding round 11 years after it was founded.
Novelos Therapeutics is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Novelos Therapeutics is a funded company, having raised a total of $53.85M across 5 funding rounds to date.
Novelos Therapeutics was established in 1998 in Madison, United States, within the biotechnology sector focused on oncology. Drugs targeting cancer treatment and diagnosis are developed, including a small-molecule agent called LIGHT. Radiation is delivered selectively by this agent to cancer cells and stem cells, addressing primary tumors, metastases, and relapse mechanisms. Operations center on advancing these therapeutic and diagnostic solutions for clinical applications.
Novelos Therapeutics's top competitors include Advanced Accelerator Applications, SOFIE and AdvanCell.
Novelos Therapeutics has made 1 acquisition, including Cellectar Biosciences.